Evinacumab Biosimilar - Research Grade

Kudo-Saito C,et al. ANGPTL3 in the peripheral circulation is associated with resistance to anti-PD1 therapy in advanced gastric cancer. Cancer Res Commun, 2026, 6 (2): 350–358.

Human

ANGPTL3

>1mg/ml

Human IgG4 S228P Kappa

https://www.imgt.org/mAb-DB/

ICH3002

Q9Y5C1

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of evinacumab, a fully human anti-ANGPTL3 antibody, supplied for research use only and not for human or veterinary use. It is a human IgG4 (S228P hinge-stabilized) kappa molecule built to recognize human angiopoietin-like 3 (ANGPTL3, UniProt Q9Y5C1), mirroring the target specificity of the originator drug without being the clinical product. It is useful as a defined, reproducible reagent for interrogating ANGPTL3 biology: binding and affinity characterization, neutralization/blockade assays against recombinant or native ANGPTL3, epitope and cross-reactivity studies, and as a positive control or benchmark antibody in assay development. The S228P substitution stabilizes the IgG4 hinge and limits Fab-arm exchange, giving consistent bivalent binding for structure-function and comparability work. Offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and available in bulk milligram-to-gram quantities to support in-vitro screening, biochemical assays, and preclinical model work requiring lot-to-lot consistency. ANGPTL3 (angiopoietin-like 3) is a secreted, liver-derived glycoprotein and a central regulator of plasma lipid metabolism. It is a member of the angiopoietin-like family, comprising an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain. ANGPTL3 inhibits two key lipolytic enzymes: lipoprotein lipase (LPL), reducing hydrolysis of triglyceride-rich lipoproteins, and endothelial lipase (EL), which acts on HDL phospholipids. By restraining LPL and EL, ANGPTL3 raises circulating triglycerides, LDL cholesterol, and HDL cholesterol. It often acts in concert with ANGPTL8 to modulate LPL activity in a tissue- and feeding-state-dependent manner. Loss-of-function ANGPTL3 variants in humans produce familial combined hypolipidemia, with broadly reduced atherogenic lipids and apparent cardiovascular protection, which established ANGPTL3 as an attractive lipid-lowering target that acts independently of the LDL-receptor pathway.

Angiopoietin-5, ANG-5, Angiopoietin-like protein 3, Angiopoietin-related protein 3, ANGPT5

Detects human/ mouse ANGPTL3

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.